Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis

Figure 1

The prompt anti-tumor effect of shikonin on osteosarcoma cells. (A) Osteosarcoma cells (K7, K12, K7M3, U2OS, 143B) were treated with shikonin in different concentrations (0, 1, 3, 5, 7.5, 10, 12.5, 15 μΜ) for 8 hours. The cell survival rate was measured by MTT assay. (B) Osteosarcoma cells (K7, K12, K7M3, U2OS, 143B) were treated with shikonin (3 μΜ) for 8, 16 or 24 hours. The cell survival rate was measured by MTT assay. (C) K7, K12, K7M3, U2OS cells were treated with shikonin (3 μΜ) while 143B cells were treated with shikonin (6 μΜ) in the absence or presence of Nec-1 (50 μΜ) for 8 hours. Nec-1 was pretreated for 2 hours before shikonin. All osteosarcoma cells had no significant changes in G0/G1, G2/M and S phases. Data are representative of 3 independent experiments.

Back to article page